AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis
AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis
复制标题
AGXT2L1 在肝细胞癌中下调并与脂肪生成异常相关
DOI：
10.1136/jclinpath-2015-203042
复制
发表时间：
2016-03-01
影响因子：
3.4
通讯作者：
Yu, Honggang
中科院分区：
文献类型：
--
作者：
Ding, Qianshan;Kang, Jian;Yu, Honggang
目的探讨丙氨酸-乙氧基酸氨基转移酶2-样基因(AGXT2L1)在肝细胞癌中的临床意义和功能作用。方法与结果免疫组织化学(IHC)染色证实AGXT2L1在肝癌组织中表达下调。我们还证明这种下调与甲胎蛋白(AFP)、血清水平和T分期等临床病理特征有关。此外，我们用Kaplan-Meier分析表明，AGXT2L1在肿瘤样本中的表达与患者预后显著相关。生物信息学工具表明，AGXT2L1在肝癌组织的脂质代谢过程中发挥作用，而siRNA沉默了AGXT2L1在肝癌97H和LM3细胞中的表达，证实了AGXT2L1的下调促进了癌细胞的脂肪生成。结论首次发现AGXT2L1在肝细胞癌中表达下调，其低表达提示预后不良。我们的研究结果还表明，AGXT2L1基因是肝细胞癌组织异常脂肪生成的关键基因。
Aims To clarify the clinical implications and functional role of the alanine-glyoxylate aminotransferase 2-like 1 (AGXT2L1) gene in hepatocellular carcinoma (HCC). Methods and results We confirmed that AGXT2L1 was down-regulated in liver cancer samples by immunohistochemical (IHC) staining. We also demonstrated that this down-regulation was associated with several clinicopathological features such as alpha fetoprotein (AFP) serum level and T stage. Furthermore, we showed with Kaplan-Meier analysis that expression of AGXT2L1 in tumour samples was significantly correlated with patient prognosis. The bioinformatic tool indicated that AGXT2L1 plays a role in the lipid metabolic process of HCC tissue, while siRNA silenced the expression of AGXT2L1 in HCC 97H and LM3 cells, confirming that down-regulation of AGXT2L1 promotes the lipogenesis of cancer cells. Conclusions For the first time, we have shown that AGXT2L1 is down-regulated in HCC and its low expression indicates a poor prognosis. Our findings also demonstrated that AGXT2L1 is a crucial gene in the abnormal lipogenesis of HCC tissue.